← 返回

微生理系统在模拟癌症中血小板病理生理学的前景

英文原题:The prospects of microphysiological systems in modeling platelet pathophysiology in cancer.

查看英文原题

The prospects of microphysiological systems in modeling platelet pathophysiology in cancer.

PubMed 2023/12/01(内容时间) Platelets Q2 · IF 3.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

血小板在血栓形成和止血中的作用已得到充分认识。然而,血小板还通过与肿瘤微环境(TME)中多种细胞的交互作用促进肿瘤进展和转移。例如,多个癌症模型不断表明,癌细胞激活后容易改变血小板功能,导致血小板-肿瘤聚集体的形成,触发血小板颗粒释放可溶性因子并改变血小板周转。

此外,活化血小板保护肿瘤细胞免受循环中的剪切力和细胞毒性自然杀伤(NK)细胞的攻击。血小板分泌的因子促进恶性细胞增殖、转移和化疗耐药。

我们对癌症中血小板生物学的许多认识是通过动物模型,特别是小鼠模型获得的。然而,这种对复杂病理生理学的临床前认识尚未在通过控制血小板功能治疗癌症的新方法方面完全实现并转化为临床试验。在这篇综述中,我们总结了通过现有体内和体外癌症模型获得的血小板生理学知识现状、血小板与TME中癌细胞的复杂相互作用以及血小板可能赋予化疗耐药的途径。由于美国政府最近通过的FDA现代化法案使动物模型在药物审批中成为可选,我们批判性地审视了利用生物工程微生理系统和器官芯片来理解血小板在癌症转移中的机制作用以及探索癌症预防和治疗新靶点的现有和未来价值。美国政府最近通过的FDA现代化法案取消了在疾病建模和药物发现过程中使用动物模型的要求。这使得工程师、科学家和工业界对应用体外细胞生物系统作为平台技术来辅助或替代动物再现人类生物学重新燃起了极大的热情。血小板在血栓形成和止血中的作用已得到充分认可。

然而,血小板还通过与肿瘤微环境中各种细胞的相互作用促进肿瘤进展和转移。在这篇综述中,我们总结了通过现有癌症模型获得的血小板生理学知识现状,并批判性地审视了利用生物工程器官芯片来增进对潜在生物学知识理解的现有和未来价值。

展开英文摘要原文

The contribution of platelets is well recognized in thrombosis and hemostasis.

However, platelets also promote tumor progression and metastasis through their crosstalk with various cells of the tumor microenvironment (TME). For example, several cancer models continue to show that platelet functions are readily altered by cancer cells upon activation leading to the formation of platelet-tumor aggregates, triggering release of soluble factors from platelet granules and altering platelet turnover.

Further, activated platelets protect tumor cells from shear forces in circulation and assault of cytotoxic natural killer (NK) cells. Platelet-secreted factors promote proliferation of malignant cells, metastasis, and chemoresistance. Much of our knowledge of platelet biology in cancer has been achieved with animal models, particularly murine.

However, this preclinical understanding of the complex pathophysiology is yet to be fully realized and translated to clinical trials in terms of new approaches to treat cancer via controlling the platelet function. In this review, we summarize the current state of knowledge of platelet physiology obtained through existing in vivo and in vitro cancer models, the complex interactions of platelets with cancer cells in TME and the pathways by which platelets may confer chemoresistance.

Since the FDA Modernization Act recently passed by the US government has made animal models optional in drug approvals, we critically examine the existing and futuristic value of employing bioengineered microphysiological systems and organ-chips to understand the mechanistic role of platelets in cancer metastasis and exploring novel therapeutic targets for cancer prevention and treatment.

The recent passage of the FDA Modernization Act by the US government has removed the requirement of the use of animal models in disease modeling and drug discovery process. This has resulted in a much-renewed excitement within engineers, scientists, and industry in applying in vitro cell biosystems as a platform technology that assists or replaces animals in reproducing human biology. The contribution of platelets is well recognized in thrombosis and hemostasis.

However, platelets also promote tumor progression and metastasis through their crosstalk with various cells of the tumor microenvironment. In this review, we summarize the current state of knowledge of platelet physiology obtained through existing cancer models and also critically examine the existing and futuristic value of employing bioengineered organ-chips to improve the knowledge of the underlying biology.

论文信息

作者
Ghosh LD、Jain A
单位
Department of Biomedical Engineering, College of Engineering, Texas A&M University, College Station, TX, USA.United States
文献类型
综述
期刊
Platelets2023 Dec
原文标识
PubMed 37610007 · DOI 10.1080/09537104.2023.2247489